It has an intimidating name, it takes nothing more than a blood draw or a saliva swab, and it is routinely misunderstood in both directions. Some people think it diagnoses celiac disease. Others think it is useless. The truth sits between the two, and it is precise: the HLA-DQ2/DQ8 test does not tell you who has celiac disease. It tells you who will not get it.

What HLA-DQ2 and DQ8 are

The HLA system is a set of genes coding for molecules on the surface of our immune cells, whose job is to present fragments of protein to the immune system. Two variants, HLA-DQ2 and HLA-DQ8, happen to be very good at presenting fragments of gluten. They are the doorway through which the autoimmune reaction of celiac disease can begin.

Two facts follow, and they carry the whole article:

  • Almost everyone with celiac disease (over 95 percent) carries DQ2 or DQ8. Without these genes, the disease is very unlikely.
  • But 30 to 40 percent of the general population carries them too, and the vast majority of those people will never develop it. The genes are necessary, not sufficient.

What the result means

A negative test (neither DQ2 nor DQ8) carries a lot of weight: it makes celiac disease very unlikely, today and for the rest of your life. That ruling-out power is the test’s genuine use.

A positive test says almost nothing. It means you are one of the third of the population who can develop the disease. It does not diagnose, does not date anything, does not predict. The diagnosis rests on antibodies and biopsy, and we walk through that route here.

Which means a positive test is never a reason to start a gluten-free diet. A negative one, on the other hand, can spare someone years of pointless monitoring.

Negative test

Neither DQ2 nor DQ8

  • Celiac disease very unlikely, for life
  • The test's genuine use
  • Spares years of pointless monitoring

Positive test

DQ2 or DQ8

  • Like a third of the population
  • Does not diagnose, does not predict
  • Never a reason to start the diet

When it is worth doing

Guidelines reserve it for specific situations, the ones where its ruling-out power actually changes something:

  1. First-degree relatives of someone with celiac disease, that is parents, children, brothers and sisters, whose risk runs at around 10 percent. The test sorts them: negatives need no celiac follow-up at all, positives get periodic blood tests, because the disease can appear at any age. This is particularly useful for the child of a celiac parent.
  2. People who already cut out gluten before any testing, and feel better for it. Antibodies and biopsy can no longer answer the question without reintroducing gluten for several weeks. The genetic test works on any diet: negative, it rules celiac disease out and points towards another explanation; positive, it settles nothing, and a gluten challenge is worth discussing with a doctor.
  3. Cases where the results contradict each other: borderline antibodies, an inconclusive biopsy, atypical symptoms. The test helps tip the balance.
  4. Certain associated conditions carrying a higher risk, such as type 1 diabetes, Down syndrome, Turner syndrome and autoimmune thyroid disease, where regular screening is recommended and a negative HLA test means it can stop.

Outside these situations, the test adds nothing. For someone eating gluten who has symptoms, an antibody blood test is simpler, cheaper and immediately useful.

Where you can get it

HLA-DQ2/DQ8 typing is a routine test, run by hospital immunology and genetics laboratories and by many commercial labs. There is nothing experimental about it.

  • In the United Kingdom, the NHS offers it within the indications set out in national guidance, usually on a gastroenterologist’s advice rather than as a first step.
  • In the United States, it is widely available through a doctor’s order. Insurance coverage varies from one plan to another, so it is worth checking before rather than after.
  • In Canada, availability and coverage depend on the province and on whether the lab work is public or private.
  • In Australia, the test is available through pathology labs on referral; whether it is covered depends on the indication, so ask when it is ordered.
  • In Europe, it is well established. Family screening is heavily practised in Italy and Spain, where the national associations describe it as part of the standard pathway, and it is covered in the recognised indications in France, Germany, Austria and Switzerland alike, on prescription.

Direct-to-consumer kits sold online exist too. They look at the same genes, but with no clinician to interpret the result, which for a test whose entire value lies in the interpretation is a serious limitation.

In practice

  • One sample, blood or saliva, ordered by a doctor.
  • Once in a lifetime: genes do not change, the result stands.
  • No need to be eating gluten beforehand.
  • A result to read with a doctor, because the lab report breaks down variants (DQ2.5, DQ2.2, DQ8, half DQ2) that do not all carry the same level of risk, and a half result is not something to interpret alone.

In summary

  • HLA-DQ2 and DQ8 are present in almost everyone with celiac disease and in a third of the population: necessary, not sufficient.
  • Negative: the disease is very unlikely, for life. Positive: possible, nothing more.
  • Useful for sorting relatives, for people who already stopped eating gluten, and in ambiguous cases.
  • It diagnoses nothing, and never justifies starting a diet.
  • Done once, with no dietary conditions attached.

This information does not replace medical advice. Ordering and interpreting an HLA test belongs with a doctor, a gastroenterologist or a paediatrician: the raw result contains nuances that do not read well on their own.